Does Pacific Edge have a target on its back?

Does Pacific Edge have a target on its back?
Invested capital in Cxbladder makes for an 'attractive acquisition target' (Image: supplied)
Brent Melville
Cancer diagnostic company Pacific Edge could be ripe for a takeover, analysis by investment firm Bell Potter suggests.Bell Potter, the Australian adviser to Pacific Edge’s September listing on the ASX, kicked off coverage of the Dunedin-based company with a speculative buy recommendation this week, valuing it at A$1.10 ($1.19) a share. That’s an 18% premium to Tuesday’s ASX price of 93 Australian cents, and a firm advance on its NZX Tuesday close of 99 cents. Local investment house Jarden pegs the NZX target price at $1.1...

More Markets

NZ sharemarket up 0.4% to end the week
Markets Market close

NZ sharemarket up 0.4% to end the week

The S&P/NZX 50 Index closed at 11,794.81, up 48.15 points or 0.41%.

Graham Skellern 05 Jul 2024
Australian shares rally as dollar hits six-month high
Markets Aus Market Wrap

Australian shares rally as dollar hits six-month high

The ASX200 has risen 1.2% to hit a nine-day high.

AAP 05 Jul 2024
NZ sharemarket down, Oz and US stocks climb
Markets Market close

NZ sharemarket down, Oz and US stocks climb

The S&P/NZX 50 Index closed at 11,746.66, down 44.26 points or 0.38%.

Graham Skellern 04 Jul 2024
Summerset anticipates flat 1H underlying profit
Markets

Summerset anticipates flat 1H underlying profit

The company is NZ's best-performing retirement village operator.

Gregor Thompson 04 Jul 2024